Inverness Medical Innovations, Inc. (IMA) on Tuesday reported a swing to profit in the third quarter ended September 30, 2009 from the same quarter last year as revenues grew significantly. Revenues were helped by a substantial increase in North American influenza sales and recent acquisitions contributing to incremental net revenue, as well as currency adjusted organic revenue growth of 9.2% in the Professional Diagnostics business.
Inverness Medical, a medical diagnostics products company, reported third quarter net income available to common stockholders of $14.3 million or $0.17 per share, compared to a net loss available to common stockholders of $9.05 million or $0.12 per share last year.
Adjusted cash basis net income available to common stockholders was $66.6 million or $0.74 per share, compared to $37.7 million or $0.46 per share, for the third quarter of 2008.
On average, 10 analysts polled by Thomson Reuters expected the company to report earnings of $0.61 per share for the quarter. Analysts' estimates typically exclude special items.
Net revenue for the quarter was $535.81 million, compared to $438.8 million in the previous year quarter. Analysts anticipated revenues of $491.73 million for the quarter.
The company recorded currency adjusted organic revenue growth of 9.2% in Professional Diagnostics business, excluding North American influenza sales. North American influenza sales totaled $40.4 million for the third quarter of 2009, compared to $6.8 million for the third quarter of 2008. Recent acquisitions contributed $37.4 million of incremental net revenue.
Gross margin for the third quarter increased to 53% on a GAAP basis, while it was 55% on a non-GAAP basis. For the year-ago quarter, gross margin was 52% on a GAAP basis and 55% on a non-GAAP basis.
Operating income for the quarter on a GAAP basis was $54.0 million and $134.5 million on a non-GAAP basis. This compares with operating income of $13.2 million and $85.5 million on a non-GAAP basis in the prior year quarter.
Net income available to common stockholders for the nine-month period was $13.873 million or $0.17 per share, compared to a net loss of $46.681 million or $0.60 loss per share in the previous year period.
The company recorded net revenue of $1.44 billion, compared to $1.21 billion in the previous year nine-month period.
IMA is currently being traded at $41.17, up $0.93 or 2.31%, on a volume of 1.26 million shares on the NYSE.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.